These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631 [TBL] [Abstract][Full Text] [Related]
54. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]
55. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355 [No Abstract] [Full Text] [Related]
56. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system. Lazarova M; Wels WS; Steinle A Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145 [TBL] [Abstract][Full Text] [Related]
57. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
58. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688 [TBL] [Abstract][Full Text] [Related]
59. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. Khurana A; Lin Y Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892 [TBL] [Abstract][Full Text] [Related]
60. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O Front Immunol; 2021; 12():780145. PubMed ID: 34975869 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]